Moderna, Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
4.2
Underperform
Overall
6.3
Hold
Quality
Health
Growth
Valuation
Sentiment
MRNA
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-145% margin).
UNH
82% of 28 covering analysts rate it Buy or Strong Buy.
⚠ limited growth momentum.
Analyst Consensus
HOLD
Target $41.42 (-12.0%)
19 analysts
BUY
Target $387.27 (+5.1%)
26 analysts
Fundamentals
MRNA
UNH
—
Trailing P/E
27.8×
-10.0×
Forward P/E
17.8×
-145.2%
Profit Margin
2.7%
-105.8%
Gross Margin
18.8%
-28.9%
ROE
12.2%
-29.8%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
1.34
Beta
0.41
—
Price / Book
—
$18.7B
Market Cap
$334.7B
$22 – $60
52-Week Range
$235 – $412
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.